Skip to main content
SpringerLink
Log in

Economic benefit of algorithm-based therapy after IFX failure

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. total healthcare costs per patient, calculated in 2012 Danish kroner and converted to US dollars

Reference

  • Steenholdt C, et al. Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab. Digestive Diseases and Sciences : 12 Feb 2015. Available from: URL: http://doi.org/10.1007/s10620-015-3581-4

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Economic benefit of algorithm-based therapy after IFX failure. PharmacoEcon Outcomes News 722, 14 (2015). https://doi.org/10.1007/s40274-015-1920-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-1920-5

Search

Navigation